Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 24, 2020 15:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Real-World Data on Telotristat Ethyl’s Antiproliferative Effects in Patients With Carcinoid Syndrome

THE WOODLANDS, Texas, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today real-world data on XERMELO’s® (telotristat ethyl) antiproliferative effects in...
January 20, 2020 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Poster Presentation at the ASCO 2020 Gastrointestinal Cancers Symposium

THE WOODLANDS, Texas, Jan. 20, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that data from a poster highlighting XERMELO® (telotristat ethyl) will be...
January 06, 2020 18:09 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Jan. 06, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
December 20, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Topline Phase 3 Data for Sotagliflozin in Type 2 Diabetes

THE WOODLANDS, Texas, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline data from the Phase 3 SOTA-EMPA study for sotagliflozin (Zynquista™) in...
December 05, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211

THE WOODLANDS, Texas, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced positive topline data from the Phase 1 multiple ascending dose study of LX9211,...
December 03, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Completes Safety Review of Initial Safety Run-in Cohort of TELE-ABC Study, a Phase 2 Clinical Study of Telotristat Ethyl in Biliary Tract Cancer

THE WOODLANDS, Texas, Dec. 03, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today the completion of a safety review of the initial run-in cohort of the...
December 02, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes

THE WOODLANDS, Texas, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that the Office of New Drugs of the U.S. Food and Drug Administration (FDA) has...
November 26, 2019 16:01 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Nov. 26, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, J.D., Executive Vice President, Corporate and...
November 14, 2019 20:09 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

THE WOODLANDS, Texas, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, President and Chief Executive Officer, will present at the...
November 07, 2019 07:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update

THE WOODLANDS, Texas, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended...